Combination therapy with lercanidipine and enalapril in the management of the hypertensive patient: an update of the evidence

References

• PageIHThe mosaic theory 32 years laterHypertension1982421777068177
   PubMed Web of Science ®Google Scholar
• PapakatsikaSStabouliSAntzaCKotsisVEarly vascular aging: a new target for hypertension treatmentCurr Pharm Des20162212212626548304
   PubMed Web of Science ®Google Scholar
• KotsisVGrassiGThe enigma of obesity-induced hypertension mechanisms in the youthJ Hypertens201634219119226682787
   PubMed Web of Science ®Google Scholar
• KotsisVNilssonPGrassiGNew developments in the pathogenesis of obesity-induced hypertensionJ Hypertens20153381499150826103132
   PubMed Web of Science ®Google Scholar
• SeverPThe heterogeneity of hypertension: why doesn’t every patient respond to every antihypertensive drug?J Hum Hypertens19959suppl 2S33S36
   PubMedGoogle Scholar
• MimranARibsteinJDuCailarGConverting enzyme inhibitors and renal function in essential and renovascular hypertensionAm J Hypertens199141 pt 27S14S2009153
   PubMed Web of Science ®Google Scholar
• DickersonJEHingoraniADAshbyMJPalmerCRBrownMJOptimisation of antihypertensive treatment by crossover rotation of four major classesLancet199935391692008201310376615
   PubMed Web of Science ®Google Scholar
• MattersonBJRedaDJCushmanWCDepartment of veterans affairs single-drug therapy of hypertension study. Revised figures and new data. Department of Veterans Affairs Cooperative Study Group on Antihypertensive AgentsAm J Hypertens1995821891927755948
   PubMedGoogle Scholar
• LawMRWaldNJMorrisJKJordanREValue of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trialsBMJ20033267404142712829555
   PubMed Web of Science ®Google Scholar
• AttwoodSBirdRBurchKWithin-patient correlation between the antihypertensive effects of atenolol, lisinopril and nifedepinJ Hypertens1994129105310607852749
   PubMed Web of Science ®Google Scholar
• ChobanianAVBakrisGLBlackHRSeventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureHypertension20034261206125214656957
   PubMed Web of Science ®Google Scholar
• BakrisGLWeirMRBlackHRImproving blood pressure control rates: is there more we can do?J Clin Hypertens (Greenwich)20079213414217268218
   PubMedGoogle Scholar
• JamersonKANwoseOJean-LouisLSchofieldLPurkayasthaDBaronMInitial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertensionAm J Hypertens200417649550115177521
   PubMed Web of Science ®Google Scholar
• TaylorAACombination drug treatment of hypertension: have we come full circle?Curr Cardiol Rep20046642142615485601
   PubMedGoogle Scholar
• WaltDSLawMMorrisJKBestwickJPWaldNJCombination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trialsAm J Med2009122329030019272490
   PubMed Web of Science ®Google Scholar
• GilesTRationale for combination therapy as initial treatment for hypertensionJ Clin Hypertens (Greenwich)200354 suppl 341112941992
   PubMedGoogle Scholar
• PadillaMCArmas-HernándezMJHernándezRHIsrailiZHValascoMUpdate on diuretics in the treatment of hypertensionAm J Ther200714215416017414583
   PubMedGoogle Scholar
• WeirMRCrikelairNLevyDRochaRKuturuVGlazerREvaluation of the dose response with valsartan and valsartan/hydrochlorothiazide in patients with essential hypertensionJ Clin Hypertens (Greenwich)20079210311217268215
   PubMedGoogle Scholar
• SowersJRNeutelJMSaundersEAntihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetesJ Clin Hypertens (Greenwich)20068747048016849900
   PubMedGoogle Scholar
• HairPIScottLJPerryCMFixed-dose combination lercanidipine/enalaprilDrugs20076719510617209666
   PubMedGoogle Scholar
• NashDTSystolic hypertensionGeriatrics200661122228
   PubMed Web of Science ®Google Scholar
• DahlofBDevereuxRBKjeldsenSELIFE Study GroupCardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololLancet20023599311995100311937178
   PubMed Web of Science ®Google Scholar
• JuliusSKjeldsenSEBrunnerHVALUE TrialVALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular riskAm J Hypertens200316754454812850387
   PubMed Web of Science ®Google Scholar
• BeckettNSPetersRFletcherAEHYVET Study GroupTreatment of hypertension in patients 80 years of age and olderN Engl J Med20083581887189818378519
   PubMed Web of Science ®Google Scholar
• YusufSSleightPPogueJBoschJDaviesRDagenaisGEffects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study InvestigatorsN Engl J Med2000342314515310639539
   PubMed Web of Science ®Google Scholar
• LiuLZhangYLiuGFEVER Study GroupThe Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patientsJ Hypertens2005232157217216269957
   PubMed Web of Science ®Google Scholar
• JamersonKWeberMABakrisGLACCOMPLISH Trial InvestigatorsBenazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patientsN Engl J Med2008359232417242819052124
   PubMed Web of Science ®Google Scholar
• DahlofBSeverPSPoulterNRASCOT InvestigatorsPrevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trialLancet200536689590616154016
   PubMed Web of Science ®Google Scholar
• PepineCJHandbergEMCooper-DeHoffRMINVEST InvestigatorsA calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomised controlled trialJAMA2003290212805281614657064
   PubMed Web of Science ®Google Scholar
• FoxKMEURopean Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease InvestigatorsEfficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)Lancet2003362938678278813678872
   PubMed Web of Science ®Google Scholar
• ChatzikyrkouCHallerHMenneJEfficacy and safety of fixed-dose Lercanidipine-Enalapril for the treatment of hypertensionClin Med200916376
   Google Scholar
• HerbetteLGVecchiarelliMSartaniALeonardiALercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular models to rationalize its pharmacokinetic propertiesBlood Press Suppl1998210179850437
   PubMedGoogle Scholar
• OteroMLManidipine-delapril combination in the management of hypertensionVasc Health Risk Manag20073325526317703633
   PubMedGoogle Scholar
• BangLMChapmanTMGoaKLLercanidipine: a review of its efficacy in the management of hypertensionDrugs200363222449247214609358
   PubMed Web of Science ®Google Scholar
• McClellanKJJarvisBLercanidipine: a review of its use in hypertensionDrugs20006051123114011129125
   PubMed Web of Science ®Google Scholar
• MeredithPALercanidipine: a novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivityExpert Opin Investig Drugs19998710431062
   PubMedGoogle Scholar
• EpsteinMLercanidipine: a novel dihydropyridine calcium-channel blockerHeart Dis2001339840711975824
   PubMedGoogle Scholar
• RoblesNROconJGomezCFLercanidipine in patients with chronic renal failure: the ZAFRA studyRen Fail2005271738015717638
   PubMed Web of Science ®Google Scholar
• BarriosVEscobarCNavarroALAURA Study GroupLercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: the LAURA studyInt J Clin Pract200660111364137017073834
   PubMed Web of Science ®Google Scholar
• BarriosVEscobarCde la FigueraMTOLERANCE studyTolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: the TOLERANCE studyCardiovasc Ther20082612918466416
   PubMed Web of Science ®Google Scholar
• PonceletPRibsteinJGoullardLBassousMGresCSClersonPEfficacy and acceptability of lercanidipine are not age dependent in patients with essential hypertension: the AGATE studyAnn Cardiol Angeiol (Paris)200453312313015291167
   PubMedGoogle Scholar
• PatchettAAThe chemistry of enalaprilBr J Clin Pharmacol198418suppl 2201S207S6085275
   PubMedGoogle Scholar
• VlassesPHLarijaniGEConnerDPFergusonRKEnalapril, a nonsulfhydryl angiotensin-converting enzyme inhibitorClin Pharm19854127402982541
   PubMedGoogle Scholar
• BarriosVEscobarCEcharriRFixed combinations in the management of hypertension: perspectives on lercanidipine – enalaprilVasc Health Risk Manag20084484785319066001
   PubMedGoogle Scholar
• Elung-JensenTHeisterbergJSonneJStrandgaardSKamperALEnalapril dosage in progressive chronic nephropathy: a randomised, controlled trialEur J Clin Pharmacol2005612879615761754
   PubMed Web of Science ®Google Scholar
• MesserliFHVasodilatory edema: a common side effect of antihypertensive therapyCurr Cardiol Rep20024647948212379167
   PubMedGoogle Scholar
• GojanovicBFeihlFLiaudetLWaeberBConcomitant calcium entry blockade and inhibition of the renin-angiotensin system: a rational and effective means for treating hypertensionJ Renin Angiotensin Aldosterone Syst2008911918404602
   PubMed Web of Science ®Google Scholar
• PuigJGCalvoCLuurilaOLercanidipine, enalapril and their combination in the treatment of elderly hypertensive patients: placebo-controlled, randomized, crossover study with four ABPMJ Hum Hypertens2007211291792417581601
   PubMed Web of Science ®Google Scholar
• AgrawalRMarxAHallerHEfficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertensionJ Hypertens200624118519216331117
   PubMed Web of Science ®Google Scholar
• MaldonadoJPereiraTTavaresAEfficacy and safety of a lercanidipine/enalapril fixed-dose combination in hypertensive patients in PortugalDrugs R D201414214715424831818
   PubMedGoogle Scholar
• DerosaGBonaventuraARomanoDEffects of enalapril/lercanidipine combination on some emerging biomarkers in cardiovascular risk stratification in hypertensive patientsJ Clin Pharm Ther201439327728524635387
   PubMed Web of Science ®Google Scholar
• CiceroAGerocarniBRosticciMBorghiCBlood pressure and metabolic effect of a combination of lercanidipine with different antihypertensive drugs in clinical practiceClin Exp Hypertens201234211311721967031
   PubMed Web of Science ®Google Scholar
• AngeloniEVitaternaALombardoPPirelliMReficeSSingle-pill combination therapy in the initial treatment of marked hypertension: a propensity-matched analysisClin Exp Hypertens201537540441025496379
   PubMed Web of Science ®Google Scholar
• CleophasTJvan OuwerkerkBMvan der MeulenJZwindermanAHDiabetics with hypertension not controlled with ACE inhibitors: alternate therapiesAngiology200152746947511515986
   PubMed Web of Science ®Google Scholar
• CiuceisCFlatiVRossiniCEffect of antihypertensive treatments on insulin signalling in lympho-monocytes of essential hypertensive patients: a pilot studyBlood Press201423633033824786779
   PubMed Web of Science ®Google Scholar
• GhiadoniLBrunoRCartoniGCombination therapy with lercanidipine and enalapril reduced central blood pressure augmentation in hypertensive patients with metabolic syndromeVascul Pharmacol2015
   PubMed Web of Science ®Google Scholar
• De CiuceisCSalvettiMRossiniCEffect of antihypertensive treatment on microvascular structure, central blood pressure and oxidative stress in patients with mild essential hypertensionJ Hypertens201432356557424378999
   PubMed Web of Science ®Google Scholar
• ManciaGCocaAChazovaIFELT Study GroupEffects on office and home blood pressure of the lercanidipine-enalapril combination in patients with Stage 2 hypertension: a European randomized, controlled clinical trialJ Hypertens20143281700170724906174
   PubMed Web of Science ®Google Scholar
• ManciaGOmboniSChazovacIFELT Study GroupEffects on the lercanidipine-enalapril combination vs. the corresponding monotherapies on home blood in hypertension: evidence from a large databaseJ Hypertens201634113914826630216
   PubMed Web of Science ®Google Scholar
• ScholzeJBramlagePTrenkwalderPKreutzREfficacy and safety of a fixed-dose combination of lercanidipine and enalapril in daily practice. A comparison of office, self-measured and ambulatory blood pressureExpert Opin Pharmacother201112182771277921999703
   PubMed Web of Science ®Google Scholar
• BorghiCPrandinMGDormiAAmbrosioniEStudy Group of the Regional Unit of the Italian Society of HypertensionImproved tolerability of the dihydropyridine calcium-channel antagonist lercanidipine: the lercanidipine challenge trialBlood Press Suppl20031142112800983
   PubMedGoogle Scholar
• AmbrosioniELeonettiGPessinaACRappelliATrimarcoBZanchettiAPatterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. Scientific Committee of the Italian Pharmacoepidemiological Survey on Antihypertensive TherapyJ Hypertens200018111691169911081785
   PubMed Web of Science ®Google Scholar
• BurnierMHessBGremingerPWaeberBDeterminants of persistence in hypertensive patients treated with Irbesartan: results of a postmarketing surveyBMC Cardiovasc Disord200551315943871
   PubMedGoogle Scholar
• VeronesiMCiceroAFPrandinMGA prospective evaluation of persistence on antihypertensive treatment with different antihypertensive drugs in clinical practiceVasc Health Risk Manag20073999100518200818
   PubMedGoogle Scholar
• RumpLCEfficacy and tolerability of the fixed lercanidipine-enalapril combination in the treatment of patients with essential hypertensionArzneimittelforschung201060312413020422943
   PubMed Web of Science ®Google Scholar